|
1
|
Le Blanc K: Immunomodulatory effects of
fetal and adult mesenchymal stem cells. Cytotherapy. 5:485–489.
2003.PubMed/NCBI
|
|
2
|
Koppula PR, Chelluri LK, Polisetti N and
Vemuganti GK: Histocompatibility testing of cultivated human bone
marrow stromal cells - a promising step towards pre-clinical
screening for allogeneic stem cell therapy. Cell Immunol.
259:61–65. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Griffin MD, Ritter T and Mahon BP:
Immunological aspects of allogeneic mesenchymal stem cell
therapies. Hum Gene Ther. 21:1641–1655. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kidd S, Caldwell L, Dietrich M, et al:
Mesenchymal stromal cells alone or expressing interferon-beta
suppress pancreatic tumors in vivo, an effect countered by
anti-inflammatory treatment. Cytotherapy. 12:615–625. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dwyer RM, Potter-Beirne SM, Harrington KA,
et al: Monocyte chemotactic protein-1 secreted in primary breast
tumors stimulates migration of mesenchymal stem cells. Clin Cancer
Res. 13:5020–5027. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Barraza RA and Poeschla EM: Human gene
therapy vectors derived from feline lentiviruses. Vet Immunol
Immunopathol. 123:23–31. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Barraza RA, Rasmussen CA, Loewen N, et al:
Prolonged transgene expression with lentivectors in the aqueous
humor outflow pathway of nonhuman primates. Hum Gene Ther.
20:191–200. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pfeifer A and Hofmann A: Lentiviral
transgenesis. Methods Mol Biol. 530:391–450. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park F: Lentivectors: are they the future
of animal transgenesis? Physiol Genomics. 31:159–173. 2007.
View Article : Google Scholar
|
|
10
|
Nakamizo A, Marini F, Amano T, et al:
Human bone marrow-derived mesenchymal stem cells in the treatment
of gliomas. Cancer Res. 65:3307–3318. 2005.PubMed/NCBI
|
|
11
|
Xiang J, Tang J, Song C, et al:
Mesenchymal stem cells as a gene therapy carrier for treatment of
fibrosarcoma. Cytotherapy. 11:516–526. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Khakoo AY, Pati S, Anderson SA, et al:
Human mesenchymal stem cells exert potent antitumorigenic effects
in a model of Kaposi’s sarcoma. J Exp Med. 203:1235–1247.
2006.PubMed/NCBI
|
|
13
|
Loebinger MR, Eddaoudi A, Davies D and
Janes SM: Mesenchymal stem cell delivery of TRAIL can eliminate
metastatic cancer. Cancer Res. 69:4134–4142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Menon LG, Picinich S, Koneru R, et al:
Differential gene expression associated with migration of
mesenchymal stem cells to conditioned medium from tumor cells or
bone marrow cells. Stem Cells. 25:520–528. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chang DY, Yoo SW, Hong Y, et al: The
growth of brain tumors can be suppressed by multiple
transplantation of mesenchymal stem cells expressing cytosine
deaminase. Int J Cancer. 127:1975–1983. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rustum Y, Cao S, Durrani F and Fakih M:
Se-(methyl)selenocysteine (MSC) potentiates the antitumor activity
of irinotecan against human tumor xenografts and protects against
drug induced toxicity. J Clin Oncol. 22(Suppl 14): 20682004.
|
|
17
|
Wang F, Dennis JE, Awadallah A, et al:
Transcriptional profiling of human mesenchymal stem cells
transduced with reporter genes for imaging. Physiol Genomics.
37:23–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kucerova L, Altanerova V, Matuskova M, et
al: Adipose tissue-derived human mesenchymal stem cells mediated
prodrug cancer gene therapy. Cancer Res. 67:6304–6313. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Amano S, Li S, Gu C, et al: Use of
genetically engineered bone marrow-derived mesenchymal stem cells
for glioma gene therapy. Int J Oncol. 35:1265–1270. 2009.PubMed/NCBI
|
|
20
|
Huang SY, Zhang DS, Han JQ, et al:
Radiosensitization and anti-tumour effects of cytosine deaminase
and thymidine kinase fusion suicide gene in human adenoid cystic
carcinoma cells. J Int Med Res. 37:479–490. 2009. View Article : Google Scholar
|
|
21
|
Rogulski KR, Wing MS, Paielli DL, et al:
Double suicide gene therapy augments the antitumor activity of a
replication-competent lytic adenovirus through enhanced
cytotoxicity and radiosensitization. Hum Gene Ther. 11:67–76. 2000.
View Article : Google Scholar
|
|
22
|
Cavarretta IT, Altanerova V, Matuskova M,
et al: Adipose tissue-derived mesenchymal stem cells expressing
prodrug-converting enzyme inhibit human prostate tumor growth. Mol
Ther. 18:223–231. 2010. View Article : Google Scholar
|
|
23
|
Uchibori R, Okada T, Ito T, et al:
Retroviral vector-producing mesenchymal stem cells for targeted
suicide cancer gene therapy. J Gene Med. 11:373–381. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mori K, Iwata J, Miyazaki M, et al:
Bystander killing effect of tymidine kinase gene-transduced adult
bone marrow stromal cells with ganciclovir on malignant glioma
cells. Neurol Med Chir. 50:545–553. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bagley RG, Weber W, Rouleau C, et al:
Human mesenchymal stem cells from bone marrow express tumor
endothelial and stromal markers. Int J Oncol. 34:619–627. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mishra PJ, Mishra PJ, Humeniuk R, et al:
Carcinoma-associated fibroblast-like differentiation of human
mesenchymal stem cells. Cancer Res. 68:4331–4339. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang SH, Park MJ, Yoon IH, et al: Soluble
mediators from mesenchymal stem cells suppress T cell proliferation
by inducing IL-10. Exp Mol Med. 41:315–324. 2009. View Article : Google Scholar : PubMed/NCBI
|
